About this Journal Submit a Manuscript Table of Contents
Stem Cells International
Volume 2013 (2013), Article ID 262438, 7 pages
http://dx.doi.org/10.1155/2013/262438
Review Article

Perspectives on the Use of Stem Cells for Autism Treatment

1Department of Experimental Medicine, Second University of Naples, Via S. Maria di Costantinopoli, 16-80138 Napoli, Italy
2Centre for Autism, La Forza del Silenzio, 81036 Caserta, Italy
3Cancellautismo, 50132 Florence, Italy
4International Child Development Resource Center, Chateau Élan, Braselton, GA 30517, USA
5Clinical Department, Cell Therapy Center EmCell, Kiev 04073, Ukraine
6Biomedical Centre for Autism Research and Treatment, 70126 Bari, Italy

Received 10 May 2013; Revised 22 August 2013; Accepted 6 September 2013

Academic Editor: Chen Lin

Copyright © 2013 Dario Siniscalco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing, Arlington, Va, USA, 4th edition, 2000.
  2. K. Williams, D. M. Wheeler, N. Silove, and P. Hazell, “Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD),” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD004677, 2010. View at Scopus
  3. J. Blake, H. E. Hoyme, and P. L. Crotwell, “A brief history of autism, the autism/vaccine hypothesis and a review of the genetic basis of autism spectrum disorders,” South Dakota Medicine, no. 58–65, 2013.
  4. J. J. Bradstreet, S. Smith, M. Baral, and D. A. Rossignol, “Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder,” Alternative Medicine Review, vol. 15, no. 1, pp. 15–32, 2010. View at Scopus
  5. X. Ming, M. Brimacombe, J. Chaaban, B. Zimmerman-Bier, and G. C. Wagner, “Autism spectrum disorders: concurrent clinical disorders,” Journal of Child Neurology, vol. 23, no. 1, pp. 6–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. T. McCracken, “Safety issues with drug therapies for autism spectrum disorders,” Journal of Clinical Psychiatry, vol. 66, supplement 10, pp. 32–37, 2005. View at Scopus
  7. D. Coury, “Medical treatment of autism spectrum disorders,” Current Opinion in Neurology, vol. 23, no. 2, pp. 131–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Siniscalco and N. Antonucci, “Possible use of Trichuris suis ova in autism spectrum disorders therapy,” Medical Hypotheses, vol. 81, no. 1, pp. 1–4, 2013. View at Publisher · View at Google Scholar
  9. D. Siniscalco, A. Sapone, A. Cirillo, C. Giordano, S. Maione, and N. Antonucci, “Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 480289, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Siniscalco, A. Giordano, and U. Galderisi, “Novel insights in basic and applied stem cell therapy,” Journal of Cellular Physiology, vol. 227, no. 5, pp. 2283–2286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Siniscalco, A. Pandolfi, and U. Galderisi, “State-of-the-art on basic and applied stem cell therapy; Stem Cell Research Italy-International Society for Cellular Therapy Europe, Joint Meeting, Montesilvano (PE)-Italy, June 10–12, 2011,” Stem Cells and Development, vol. 21, no. 5, pp. 668–669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Siniscalco, “Stem cell research: an opportunity for autism spectrum disorders treatment,” Autism, vol. 2, no. 2, article e106, 2012. View at Publisher · View at Google Scholar
  13. S. Razavi, M. R. Razavi, H. Zarkesh Esfahani, M. Kazemi, and F. S. Mostafavi, “Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells,” Development, Growth & Differentiation, vol. 55, no. 6, pp. 648–655, 2013.
  14. D. Drago, C. Cossetti, N. Iraci et al., “The stem cell secretome and its role in brain repair,” Biochimie, 2013. View at Publisher · View at Google Scholar
  15. G. P. Zheng, M. H. Ge, Q. Shu, M. Rojas, and J. Xu, “Mesenchymal stem cells in the treatment of pediatric diseases,” World Journal of Pediatrics, vol. 9, no. 3, pp. 197–211, 2013. View at Publisher · View at Google Scholar
  16. D. Siniscalco, C. Giordano, U. Galderisi et al., “Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice,” Frontiers in Integrative Neuroscience, vol. 5, article 79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. V. I. Zemel'ko, I. B. Kozhukharova, L. L. Alekseenko et al., “Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study,” Tsitologiia, vol. 55, no. 2, pp. 101–110, 2013.
  18. D. Siniscalco, A. Sapone, C. Giordano et al., “The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients,” Journal of Autism and Developmental Disorders, vol. 42, no. 7, pp. 1403–1410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Yabut and H. S. Bernstein, “The promise of human embryonic stem cells in aging-associated diseases,” Aging, vol. 3, no. 5, pp. 494–508, 2011. View at Scopus
  20. M. Evans, “Discovering pluripotency: 30 years of mouse embryonic stem cells,” Nature Reviews Molecular Cell Biology, vol. 12, no. 10, pp. 680–686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. F. Pera, B. Reubinoff, and A. Trounson, “Human embryonic stem cells,” Journal of Cell Science, vol. 113, part 1, pp. 5–10, 2000. View at Scopus
  22. C. Tang, I. L. Weissman, and M. Drukker, “Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives,” Methods in Molecular Biology, vol. 1029, pp. 17–31, 2013. View at Publisher · View at Google Scholar
  23. S. A. Jackson, J. Schiesser, E. G. Stanley, and A. G. Elefanty, “Differentiating embryonic stem cells pass through ‘temporal windows’ that mark responsiveness to exogenous and paracrine mesendoderm inducing signals,” PLoS ONE, vol. 5, no. 5, Article ID e10706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. S. Ng, R. P. Davis, L. Azzola, E. G. Stanley, and A. G. Elefanty, “Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation,” Blood, vol. 106, no. 5, pp. 1601–1603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Nakamura, T. Hiroyama, K. Miharada, and R. Kurita, “Red blood cell production from immortalized progenitor cell line,” International Journal of Hematology, vol. 93, no. 1, pp. 5–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Senju, S. Hirata, Y. Motomura et al., “Pluripotent stem cells as source of dendritic cells for immune therapy,” International Journal of Hematology, vol. 91, no. 3, pp. 392–400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Siniscalco, C. Giordano, U. Galderisi et al., “Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice,” Cellular and Molecular Life Sciences, vol. 67, no. 4, pp. 655–669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Aleckovic and C. Simón, “Is teratoma formation in stem cell research a characterization tool or a window to developmental biology?” Reproductive Biomedicine Online, vol. 17, no. 2, pp. 270–280, 2008. View at Scopus
  29. B. Blum and N. Benvenisty, “The tumorigenicity of human embryonic stem cells,” Advances in Cancer Research, vol. 100, pp. 133–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Leeb, M. Jurga, C. Mcguckin et al., “New perspectives in stem cell research: beyond embryonic stem cells,” Cell Proliferation, vol. 44, supplement 1, pp. 9–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Aznar and J. L. Sánchez, “Embryonic stem cells: are useful in clinic treatments?” Journal of Physiology and Biochemistry, vol. 67, no. 1, pp. 141–144, 2011. View at Publisher · View at Google Scholar
  32. E. Callaway, “Stem cells that are pure enough for the clinic,” Nature, 2011. View at Publisher · View at Google Scholar
  33. C. Dennis, “Clinical-use stem cells made in Singapore,” Nature, 2006. View at Publisher · View at Google Scholar
  34. C. Lok, “Stem-cell research: never say die,” Nature, vol. 481, no. 7380, pp. 130–133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. F. Pera, “Stem cells: the dark side of induced pluripotency,” Nature, vol. 471, no. 7336, pp. 46–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. A. Klemmt, V. Vafaizadeh, and B. Groner, “The potential of amniotic fluid stem cells for cellular therapy and tissue engineering,” Expert Opinion on Biological Therapy, vol. 11, no. 10, pp. 1297–1314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Galende, I. Karakikes, L. Edelmann et al., “Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells,” Cellular Reprogramming, vol. 12, no. 2, pp. 117–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Laguna Goya, R. Busch, R. Mathur, A. J. Coles, and R. A. Barker, “Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation,” Neurobiology of Disease, vol. 41, no. 2, pp. 407–414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. P.-M. Chen, M.-L. Yen, K.-J. Liu, H.-K. Sytwu, and B.-L. Yen, “Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells,” Journal of Biomedical Science, vol. 18, no. 1, article 49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Abdulrazzak, D. Moschidou, G. Jones, and P. V. Guillot, “Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues,” Journal of the Royal Society Interface, vol. 7, supplement 6, pp. S689–S706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. P. V. Guillot, C. Gotherstrom, J. Chan, H. Kurata, and N. M. Fisk, “Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC,” Stem Cells, vol. 25, no. 3, pp. 646–654, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Piroth, M. C. Pauly, C. Schneider et al., “Transplantation of human fetal tissue for neurodegenerative diseases: validation of a new protocol for microbiological analysis and bacterial decontamination,” Cell Transplantation, 2013. View at Publisher · View at Google Scholar
  43. S. Uchida, Y. Inanaga, M. Kobayashi, S. Hurukawa, M. Araie, and N. Sakuragawa, “Neurotrophic function of conditioned medium from human amniotic epithelial cells,” Journal of Neuroscience Research, vol. 62, pp. 585–590, 2000.
  44. N. Sakuragawa, M. A. Elwan, S. Uchida, T. Fujii, and K. Kawashima, “Non-neuronal neurotransmitters and neurotrophic factors in amniotic epithelial cells: expression and function in humans and monkey,” Japanese Journal of Pharmacology, vol. 85, no. 1, pp. 20–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. H.-C. Pan, D.-Y. Yang, S.-P. Ho et al., “Escalated regeneration in sciatic nerve crush injury by the combined therapy of human amniotic fluid mesenchymal stem cells and fermented soybean extracts, Natto,” Journal of Biomedical Science, vol. 16, no. 1, article 75, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Siniscalco, “Transplantation of human mesenchymal stem cells in the study of neuropathic pain,” Methods in Molecular Biology, vol. 617, pp. 337–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Arthur, A. Zannettino, and S. Gronthos, “The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair,” Journal of Cellular Physiology, vol. 218, no. 2, pp. 237–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Brooke, M. Cook, C. Blair et al., “Therapeutic applications of mesenchymal stromal cells,” Seminars in Cell and Developmental Biology, vol. 18, no. 6, pp. 846–858, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Short, N. Brouard, T. Occhiodoro-Scott, A. Ramakrishnan, and P. J. Simmons, “Mesenchymal stem cells,” Archives of Medical Research, vol. 34, no. 6, pp. 565–571, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Beyer Nardi and L. da Silva Meirelles, “Mesenchymal stem cells: isolation, in vitro expansion and characterization,” Handbook of Experimental Pharmacology, no. 174, pp. 249–282, 2006. View at Scopus
  51. P. S. Frenette, S. Pinho, D. Lucas, and C. Scheiermann, “Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine,” Annual Review of Immunology, vol. 31, pp. 285–316, 2013. View at Publisher · View at Google Scholar
  52. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Bernstein, I. Sperling, D. Corbeil, U. Hempel, and S. Fickert, “Progenitor cells from cartilage—no osteoarthritis-grade-specific differences in stem cell marker expression,” Biotechnology Progress, vol. 29, no. 1, pp. 206–212, 2013. View at Publisher · View at Google Scholar
  54. S. Huang, V. Leung, S. Peng et al., “Developmental definition of MSCs: new insights into pending questions,” Cellular Reprogramming, vol. 13, no. 6, pp. 465–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Pascucci, G. Curina, F. Mercati et al., “Flow cytometric characterization of culture expanded multipotent mesenchymal stromal cells (MSCs) from horse adipose tissue: towards the definition of minimal stemness criteria,” Veterinary Immunology and Immunopathology, vol. 144, no. 3-4, pp. 499–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Siniscalco, N. Sullo, S. Maione, F. Rossi, and B. D'Agostino, “Stem cell therapy: the great promise in lung disease,” Therapeutic Advances in Respiratory Disease, vol. 2, no. 3, pp. 173–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Le Blanc and M. F. Pittenger, “Mesenchymal stem cells: progress toward promise,” Cytotherapy, vol. 7, no. 1, pp. 36–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. C. E. Petrie Aronin and R. S. Tuan, “Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells,” Birth Defects Research C, vol. 90, no. 1, pp. 67–74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Meyerrose, S. Olson, S. Pontow et al., “Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors,” Advanced Drug Delivery Reviews, vol. 62, no. 12, pp. 1167–1174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. P. A. Sotiropoulou and M. Papamichail, “Immune properties of mesenchymal stem cells,” Methods in Molecular Biology, vol. 407, pp. 225–243, 2007. View at Scopus
  61. R. E. Newman, D. Yoo, M. A. LeRoux, and A. Danilkovitch-Miagkova, “Treatment of inflammatory diseases with mesenchymal stem cells,” Inflammation and Allergy—Drug Targets, vol. 8, no. 2, pp. 110–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Ksi̧zek, “A comprehensive review on mesenchymal stem cell growth and senescence,” Rejuvenation Research, vol. 12, no. 2, pp. 105–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. M. K. Majumdar, M. A. Thiede, J. D. Mosca, M. Moorman, and S. L. Gerson, “Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells,” Journal of Cellular Physiology, vol. 176, pp. 57–66, 1998.
  64. L. da Silva Meirelles, A. M. Fontes, D. T. Covas, and A. I. Caplan, “Mechanisms involved in the therapeutic properties of mesenchymal stem cells,” Cytokine and Growth Factor Reviews, vol. 20, no. 5-6, pp. 419–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Giuliani, M. Fleury, A. Vernochet et al., “Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation,” PLoS ONE, vol. 6, no. 5, Article ID e19988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. M. J. Hoogduijn, F. Popp, R. Verbeek et al., “The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy,” International Immunopharmacology, vol. 10, no. 12, pp. 1496–1500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Dazzi and F. M. Marelli-Berg, “Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells,” European Journal of Immunology, vol. 38, no. 6, pp. 1479–1482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Tatara, K. Ozaki, Y. Kikuchi et al., “Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation,” Cytotherapy, vol. 13, no. 6, pp. 689–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Ashwood, B. A. Corbett, A. Kantor, H. Schulman, J. van de Water, and D. G. Amaral, “In search of cellular immunophenotypes in the blood of children with autism,” PLoS ONE, vol. 6, no. 5, Article ID e19299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Suzuki, H. Matsuzaki, K. Iwata et al., “Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders,” PLoS ONE, vol. 6, no. 5, Article ID e20470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Gupta, D. Samra, and S. Agrawal, “Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin,” Journal of Clinical Immunology, vol. 30, no. 1, pp. S90–S96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. A. M. Enstrom, C. E. Onore, J. A. van de Water, and P. Ashwood, “Differential monocyte responses to TLR ligands in children with autism spectrum disorders,” Brain, Behavior, and Immunity, vol. 24, no. 1, pp. 64–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Siniscalco, A. Sapone, C. Giordano et al., “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders,” Journal of Autism and Developmental Disorders, 2013. View at Publisher · View at Google Scholar
  74. A. L. Oblak, D. L. Rosene, T. L. Kemper, M. L. Bauman, and G. J. Blatt, “Altered posterior cingulate cortical cyctoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism,” Autism Research, vol. 4, no. 3, pp. 200–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. E. R. Whitney, T. L. Kemper, D. L. Rosene, M. L. Bauman, and G. J. Blatt, “Density of cerebellar basket and stellate cells in autism: evidence for a late developmental loss of Purkinje cells,” Journal of Neuroscience Research, vol. 87, no. 10, pp. 2245–2254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Courchesne, C. M. Karns, H. R. Davis et al., “Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study,” Neurology, vol. 57, no. 2, pp. 245–254, 2001. View at Scopus
  77. M. L. Bauman and T. L. Kemper, “Neuroanatomic observations of the brain in autism: a review and future directions,” International Journal of Developmental Neuroscience, vol. 23, no. 2-3, pp. 183–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. R. C. Rodrigues Hell, M. M. Silva Costa, A. M. Goes, and A. L. R. Oliveira, “Local injection of BDNF producing mesenchymal stem cells increases neuronal survival and synaptic stability following ventral root avulsion,” Neurobiology of Disease, vol. 33, no. 2, pp. 290–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. Y.-K. Chang, M.-H. Chen, Y.-H. Chiang et al., “Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells,” Journal of Biomedical Science, vol. 18, no. 1, article 54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Li and J. Jiang, “Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms,” Frontiers of Medicine in China, vol. 5, no. 1, pp. 33–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Miyake, T. Hirasawa, T. Koide, and T. Kubota, “Epigenetics in autism and other neurodevelopmental diseases,” Advances in Experimental Medicine and Biology, vol. 724, pp. 91–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Witkowska-Zimny and K. Walenko, “Stem cells from adipose tissue,” Cellular and Molecular Biology Letters, vol. 16, no. 2, pp. 236–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Locke, V. Feisst, and P. R. Dunbar, “Concise review: human adipose-derived stem cells: separating promise from clinical need,” Stem Cells, vol. 29, no. 3, pp. 404–411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Witkowska-Zimny and E. Wrobel, “Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion,” Cellular and Molecular Biology Letters, vol. 16, no. 3, pp. 493–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Zhou, B. Yang, Y. Tian et al., “Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes,” Cellular Immunology, vol. 272, no. 1, pp. 33–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. M. M. Carvalho, F. G. Teixeira, R. L. Reis, N. Sousa, and A. J. Salgado, “Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine,” Current Stem Cell Research and Therapy, vol. 6, no. 3, pp. 221–228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Y.-C. Hsu, D.-C. Lee, and I.-M. Chiu, “Neural stem cells, neural progenitors, and neurotrophic factors,” Cell Transplantation, vol. 16, no. 2, pp. 133–150, 2007. View at Scopus
  88. H. E. Stevens, K. M. Smith, B. G. Rash, and F. M. Vaccarino, “Neural stem cell regulation, fibroblast growth factors, and the developmental origins of neuropsychiatric disorders,” Frontiers in Neuroscience, vol. 4, article 59, 2010.
  89. J. D. Buxbaum, “Multiple rare variants in the etiology of autism spectrum disorders,” Dialogues in Clinical Neuroscience, vol. 11, no. 1, pp. 35–43, 2009. View at Scopus
  90. G. Martino, M. Bacigaluppi, and L. Peruzzotti-Jametti, “Therapeutic stem cell plasticity orchestrates tissue plasticity,” Brain, vol. 134, part 6, pp. 1585–1587, 2011. View at Publisher · View at Google Scholar · View at Scopus